| 5.15 0.29 (5.97%) | 06-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.76 | 1-year : | 7.51 |
| Resists | First : | 5.79 | Second : | 6.42 |
| Pivot price | 5.13  |
|||
| Supports | First : | 4.76 | Second : | 3.96 |
| MAs | MA(5) : | 4.93 |
MA(20) : | 5.27 |
| MA(100) : | 6.93 |
MA(250) : | 7.63 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 12.4 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 11.3 | Low : | 4.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CVRX ] has closed below upper band by 49.0%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.3 - 5.34 | 5.34 - 5.37 |
| Low: | 4.98 - 5.02 | 5.02 - 5.05 |
| Close: | 5.1 - 5.16 | 5.16 - 5.21 |
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Tue, 09 Jun 2026
CVRx CFO Jared Oasheim to step down after decade with company - Investing.com
Tue, 09 Jun 2026
Medical device firm CVRx plans CFO change, keeps him through Feb. 2027 - Stock Titan
Tue, 09 Jun 2026
CVRx Announces Chief Financial Officer Transition - GlobeNewswire
Thu, 04 Jun 2026
CVRx, Inc. (CVRX) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow - Seeking Alpha
Wed, 03 Jun 2026
[Form 3] CVRx, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Wed, 03 Jun 2026
CVRx (NASDAQ: CVRX) director Nielsen awarded shares and 11,182-share option - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 27 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 9.5 (%) |
| Held by Institutions | 63.5 (%) |
| Shares Short | 1,940 (K) |
| Shares Short P.Month | 1,750 (K) |
| EPS | -2.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.1 |
| Profit Margin | -89.2 % |
| Operating Margin | -82.4 % |
| Return on Assets (ttm) | -27.3 % |
| Return on Equity (ttm) | -107 % |
| Qtrly Rev. Growth | 19.6 % |
| Gross Profit (p.s.) | 1.91 |
| Sales Per Share | 2.22 |
| EBITDA (p.s.) | -1.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -2.57 |
| PEG Ratio | 0 |
| Price to Book value | 4.68 |
| Price to Sales | 2.31 |
| Price to Cash Flow | -3.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|